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ABSTRACT 
Objective: The objective of the present study is to compare the prescribing patterns and cost of illness of Rheumatoid arthritis patients in two 
different hospitals. 
Methods: This is an observational study conducted in two different tertiary care hospitals in Salem district after obtaining approval of the 
Institutional Ethics Committee (IEC) (Registration Number EC/PHARM D/2019.06). A sample size of 102 (above 18 y) patients were included (52 
from group 1 hospital and 50 from group 2 hospital). The study was conducted over a period of 6 mo from February 2019 to July 2019. The cost was 
collected by a patient face-to-face interview. 
Results: Out of 102 patients, females (57.84%) patients were more prevalent than men with the age group of 50-59 y in both groups. Methotrexate 
was most commonly prescribed drug in group 1(36.5%), whereas in group 2 are Sulfasalazine (37%). Among the DMARDs unit cost of methotrexate 
is high but the monthly cost was high for Sulfasalazine, because the methotrexate is prescribed on a once-weekly basis while sulfasalazine is taken 
twice a day. The cost of NSAIDs comes around 46.47% of the total drug cost of the month. In steroids, cost comes around 11.73% of the total drug 
cost. Among the direct cost of two groups, the drug cost and transportation cost is higher when compared with other costs. Indirect costs such as 
lost wages, due to disease is higher in group 1. 
Conclusion: The study concluded that the burden of RA to the patient is huge, Appropriate standard prescribing guidelines should be developed 
and implementation of the rational drug must be promoted. Polypharmacy was reported in group 1 hospital, the progression of symptoms was the 
same in both hospitals, it increases the cost of therapy and overall cost of patients. Hence it becomes vital to diagnose and control the disease at an 
early stage to control the economic burden on the patient. 
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INTRODUCTION  
Rheumatoid arthritis is an autoimmune disorder that causes joint 
pain and damage throughout the body. It mainly affects joints, 
connective tissues, muscles, tendons and fibrous tissues (WHO 
definition). Uncontrolled inflammatory reaction of the disease may 
lead to joint damage, functional disability, decreased quality of life 
and increased mortality. Autoimmune disease is an illness that 
occurs when the body tissue mistakenly attacks normal healthy 
cells. The abnormal immune response causes inflammation and 
thickening of the membrane (synovium) that lines the joints. 
Inflammation of the synovium is called synovitis [1].  
The worldwide annual incidence of RA is approximately 3 cases per 
10,000 populations and the prevalence rate is estimated at around 
1% affecting women two to three times more than men. It is 
reported that in India, the prevalence of RA is 0.75%. This indicates 
that in India there are more than one crore patients affected by this 
devastating disease [2]. 
The main aim of the treatment of RA is relieving pain, reducing joint 
swelling slowing or preventing joint damage, improving the physical 
function and wellbeing. The drugs used for RA include Disease-
Modifying Anti-Rheumatic drugs (DMARDs), Non-Steroidal Anti-
inflammatory Drugs (NSAIDs), Biological Agents and Corticosteroids 
[1]. Nonpharmacological treatments include physical therapy, 
modified exercise programs and devices that ease physical stress on 
the joints. People with RA are also encouraged to make lifestyle 
changes such as balancing activity with rest, eating a healthy diet 
and reducing emotional stress [2]. 
Pharmacoeconomics is defined as the branch of health economics 
which deals with the measurement of both the costs and 
consequences. Generally, the cost can be categorized into 3 
categories-direct cost, indirect cost and intangible cost. Direct 
medical cost covers direct medical cost and direct non-medical cost. 
Direct medical cost includes the cost of the consultation, 
hospitalization cost, medical staff cost, administrative cost, 
diagnostic tests and procedures and medication cost. Direct non-
medical costs include food cost and transportation cost. Indirect cost 
is due to lost productivity including an absence of duties, sick leaves, 
early retirement etc. Intangible costs are defined as pain and 
suffering of a patient which are excluded from the study. 
Pharmacoeconomics deals with cost and outcome of therapy. The 
outcome in RA has been described in different studies, mainly in 
terms of mortality, radiographic changes and functional disability 
scores. The most important factors affected by patients are pain or 
stiffness in joints and increasing economic loss depending on ability 
and loss of or changes in employment during the course of RA [3]. 
MATERIALS AND METHODS 
Study design and ethical considerations 
This was an observational study conducted in the inpatient and 
outpatient departments of two different tertiary care hospitals in 
Salem obtaining approval of the Institutional Ethics Committee (IEC) 
(Registration Number EC/PHARM D/2019.06). 102 patients were 
enrolled in the study. This study was conducted for a period of 6 mo 
from February 2019 to July 2019. Patients who met the inclusion 
criteria were enrolled in the study. All information relevant to the 
study was collected from case records. The sociodemographic 
characters such as age, gender, marital status, employment status, 
education status and disease duration were collected by patient face 
to face interview. The cost of medicines was obtained from the bill of 
pharmacy from where they purchase medicines so that the cost to 
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patients can be measured. In addition, the cost of the diagnostic tests 
was obtained from the laboratory of the hospital. The indirect costs 
such as productivity loss of patient and productivity loss of family 
were calculated. All the costs were added up for each patient and for 
all patients to obtain the total. Patients above 18 y and patient on 
stable therapy with RA more than 3 mo are included in this study. 
Data analysis and interpretations 
The study subjects were described in respect of their demographic 
profiles according to their age and gender. The continuous variables 
of both groups were analyzed and interpreted by the student “T” 
test. The categorical variables of them were analyzed and 
interpreted by the χ2
A total of 102 were enrolled in the study (52 from group 1 hospital 
and 50 from group 2 hospital). Among them, 59 females and 53 male 
patients. The percentage of females was 57.84% and those of males 
were 51.96%. Majority of people belong to the age group of 50-59 y 
in both groups 25% and 42% respectively. This was followed by 
daily wages (7.2%), professionals (6.2%), Student (2%), Patient 
retired from the service (1%). and whereas in group 2-
24(12%)patient’s population consist of daily wages, followed by 
housewives (8%), Professionals (2.5%), Business (2. 5%). Duration 
of the disease extends from over less than one year to more than 20 
y. Both group patients had less time span (0-2 y). In group 1 48.07% 
and group 2 80% of the patients had the disease duration of 0-2 y. In 
group 1 20(38.46%) patients had disease duration of 3-5 y and in 
group is16%. Only 5.76 % of the patients had the disease for about 
6-8 y in group 1, whereas in group 2 is 2%. In group 1 7.46% of the 
patient had the disease duration of 9-11 y, whereas in group 2 is 2%. 
 (Chi-square) test. The above statistical 
procedures were undertaken with the help of the statistical package 
namely IBM SPSS Statistics-20. The P-values less than or equal to 
0.05 (P ≤0.05) was fixed as the level of significance. 
RESULTS 
During the current treatment, all the patients were prescribed with 
DMARDs which is the first line drug for RA. Methotrexate is highly 
prescribed drug in group 1(36.5%), Sulfasalazine is highly 
prescribed drug in group 2 (37%). Other drug such as 
Hydroxychloroquine 21.5% in group 1, whereas in group 2 is 6% 
7.46% of Leflunomide is used in group 1 only. Most frequently used 
combination of the drug was 2 DMARDs i.e., 
Methotrexate+Sulfasalazine, 11.5% in group 1 and group 2 is 4%. 
Other drugs such as Methotrexate+Hydroxychloroquine 9.61% in 
group 1 and group 2 is10 % in table 1. 
 
Table 1: Total number of patients taking DMARDs 
 Dmadrs No. of patient involved 
Group 1 Group 2 
Methotrexate  19 (36.5%) 10(20%) 
Hydroxychloroquine 11(21.5%) 3(6%) 
Sulfasalazine 4(7.69%) 37(74%) 
Leflunomide 4(7.69) 0 
Methotrexate+Sulfasalazine 6(11.53) 2(4%) 
Methotrexate+Hydroxychloroquine 5(9.61%) 5(10%) 
Methotrexate+Leflunomide 1(1.92%) 0 
Hydroxychloroquine+Sulfasalazine 0 5(10%) 
Methotrexate+Hydroxychloroquine+Leflunomide 6(11.53%) 0 
Methotrexate+Hydroxychloroquine+Sulfasalazine 2(3.84%) 0 
Among DMARDs, the unit cost of Methotrexate (0.17%) was high when compared with other DMARDs in group 1, but the monthly cost of 
leflunomide was high. Leflunomide consumes about 0.75% of drug cost per month followed by Hydroxychloroquine 0.26% and Sulfasalazine 0.56%. 
 
In biological agent, Rituximab (50.4%) cost was high when 
compared with other biological agent. The cost of NSAIDs comes 
around 2.36% of the total drug cost of month. In steroids cost comes 
around 0.59 % of the total drug cost 
 
Table 2: Total drug cost per month in group 1 and group 2 
Drugs Group 1 Group 2 
Unit 
price 
Cost of drug/month % Drug cost Unit 
price 
Cost of 
drug/month 
% Drug cost 
DMARDs 
Methotrexate 32 128 0.17 11 88 7.05 
Hydroxychloroquine 6.23 186.9 0.26 6.47 194.1 15.5 
Sulfasalazine 18 540 0.75 5.47 328 25 
Leflunomide 5.47 328 0.56 0 0 0 
Biological agent 
Adalimumab 25000 25000 35 0 0 0 
Etanercept 7000 7000 9.81 0 0 0 
Rituximab 36000 36000 50.4 0 0 0 
NSAIDs 
Bromelain+Trypsin+RutosideTrihydrate 17.1 1026 1.43 0 0 0 
Piroxicam 13 585 0.82 7.50 225 18 
Diclofenac gel 79 79 0.11 72 72 5.5 
STEROIDS 
Triamcinolone acetonide 6.7 201 0.28 0 0 0 
Deflazacort 7.5 225 0.31 8.90 267 21.3 
 
Among DMARDs, the total cost of Sulfasalazine (25%) was high when 
compared with other DMARDs. Hydroxychloroquine consumes about 
15.5% and Methotrexate (7.05%). In Group 2 there is no biological 
agent taken, the cost of NSAIDs comes around 32% of the total drug 
cost of month. Steroids come around 21.3% of the total drug cost. The 
direct medical cost was higher in group 1 in both reviews. 
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Table 3: Comparison of direct medical costs between the two groups at R1 and R2 
COST  Group 1 (Review 1)  Group 2 (Review 1)  Significance 
Mean SD % Cost Mean SD % Cost 
Drug 4642.61 791.58 31.84 1433.24 1009.01 16.66 P=0.005 
Consultation 590.38 517.63 3.54 225.00 61.65 2.61 P<0.001 
Lab Cost 1767.31 3398.96 12.12 810.00 423.90 9.41 P=0.051 
Radiology cost 438.46 334.98 4.0 523.00 204.34 6.08 P=0.129 
Surgical 6634.61 21956.31 45.51 5300 29561.5 61.62 P=0.067 
Hospital 505.19 723.26 3.46 308.94 293.25 3.59 P<0.001 
Total Direct cost 14577.88 27,722,72 100 8600.18 32,379.27 100 P=0.4297 
 
Table 4: Comparison of direct non-medical cost between two groups 
Cost Review Group 1  Group 2  Significance 
Mean SD % Cost Mean SD % Cost 
Transport R1 374.23 418.74 56.14 285.76 176.49 64.58 P=0.171 
 R2 343.3 439.69 59.5 181.00 122.96 68.5 P=0.035 
Food R1 292.30 301.85 43.85 156.72 187.40 35.41 P=0.008 
 R2 233.08 249.09 40.43 83.0 39.29 31.4 P<0.001 
Total R1 666.53 720.85 100 442.48 357.89 100 P =0.0246 
R2 576.38 688.78 100 264 162.25 100 P= 0.0012 
 
Table 5: Comparison of indirect cost between the two groups at R1 and R2 
Cost Review  Group 1  Group 2  Significance 
Mean SD % Cost Mean SD % Cost 
Self-production R1 447.11 619.64 46.43 386.0 437.76 76.79 P=0.568 
R2 434.61 621.78 31.1 276.00 306.43 69.34 P=0.108 
Family product loss R1 515.38 553.91 53.54 205.00 305.58 24.68 P=0.001 
R2 453.85 554.03 32.48 122.0 177.61 44.62 P<0.001 
Indirect cost R1 962.49 1173.55 100 591 743.34 100 P =0.0293 
R2 1397 1175.81 100 398 484.61 100 P=<0.0001 
  
DISCUSSION 
102 patients were enrolled in the study. Female patients (57.84%) 
were more prevalent than male patients (42.17%). Similar 
prevalence was found in studies carried out by Vidhya Alex et al. 
(82.5%) [2] and There were 628 females and 161 male 
[10], Nagappa AN et al., [8], female to male ratio is3:1. The age group 
distribution in both groups between 50-59 y constitutes with 25% 
and 42%, which is the highest percentage, whereas the study 
conducted by Vidhya Alex et al., [2], reports that mean age was 
52.6±10.89, mean age is 40.57±13.69. The majority of the patients 
were married category in both groups (90.4%) and (84.0%), 
whereas the study conducted by Vidhya Alex et al., [2] with mean 
age 47.6Â±12.6 and 47.1Â±14.4 y respectively [3]. reports that 
(90%) of the patient belong to married category. The educational 
status of the patient in group-1 is primary category (32.7%) and in 
group-2 is secondary category (70%), similar results were reported 
in Vidhya Alex et al., [5], that majority of the patients in secondary 
category (34%). Occupational status shows that 21 % of the patient 
population consist of house wives in group 1. This was followed by 
daily wages (7.2%), professionals (6.2%), Student (2%), Patient 
retired from the service (1%). and whereas in group 2-24(12%) 
patient population consists of daily wages, followed by housewives 
(8%), Professionals (2.5%), Business (2.5%). While a study 
conducted by Vidhya Alex et al., [5], shows the majority of the 
population consists of housewives (66%), followed by (10%), 
patients who retired from their services (7.5%), patients who 
worked for daily wages (6.5%), patients with desk jobs (3%)and the 
unemployed population consists of (2%) of the study population. 
In this study, Methotrexate were highly used in Group-1(36.5%), 
whereas in Group-2 is Sulfasalazine (74%). Other studies such as 
Vidhya Alex et al.,[2], Peter Tug well et al. [4], in the USA and Canada 
reported that highly used drug is In this study, Methotrexate were 
highly used in Group-1(36.5%), whereas in Group-2 is Sulfasalazine 
(74%) show sthat Methotrexate+Hydroxy chloroquine a highly 
prescribed drug. In this study NSAID-Bromelain+Trypsin+Rutoside 
Trihydrate (40.38%) is highly prescribed in Group1 and in Group 2 
Piroxicam (88%) is a highly prescribed drug. The other study such 
as Vidhya Alex et al., [2], reported that the frequently used NSAID 
has been Etoricoxib (6.5%), G In this study, Methotrexate were 
highly used in Group-1(36.5%), whereas in Group-2 is Sulfasalazine 
(74%). Other studies such as Vidhya Alex et al., [2], and Nyi Mekar 
also repoted there are 20.81% of patients were given MTX, 4.17% 
[5]. Peter Tug well et al. [4] in the USA and Canada reported that 
highly used drug is In this study, Methotrexate were highly used in 
Group-1(36.5%), whereas in Group-2 is Sulfasalazine (74%). 
reported that Indomethacin (77%) is highly prescribed drug. The 
biological agents such as Adalimumab (3.8%), Etanercept (5.8%) 
and Rituximab (1.9%) were present in the RA group only. No 
biological agents were present in the ortho group. Another study 
such as Kowalik et al.2018, reported that Adalimumab (21%), 
Etanercept (37%) is a highly prescribed drug. In our study 
Triamcinolone Acetonide (19.2%) is highly prescribed in group 1 
and group 2 Deflazacort (28%) is highly prescribed, whereas the 
study conducted by Vidhya Alex et al., [2], reports that Deflazacort is 
a highly prescribed steroid, Gawde et al., [6reports that 
Prednisolone (n=22) is used in the study. Folic acid tablets were 
used in both groups 69.2% and 24%. Calcium tablets were used in 
both groups 28.8% and 62% and Multivitamin tablets also used in 
both groups 46.15% and 54%. Other drugs such as anti-ulcer drugs 
(113.4%) in RA group and 94% in ortho group, In RA group anti 
emetics (58%) were used and ortho group 10% were used those 
drugs. Other studies such as Vidhya Alex et al., [2], reveals that 
Diclofenac gel (2.5%), Calcium and Multivitamin tablet (51.5%) is 
commonly prescribed. Gwade et al.,[6], reports that Calcium 
supplements (n=69) are commonly prescribed. 
Among DMARDs, the unit cost of Methotrexate (0.17%) was high 
when compared with other DMARDs in group 1, but the monthly cost 
of leflunomide was high. Leflunomide consumes about 0.75% of drug 
cost per month followed by Hydroxychloroquine 0.26% and 
Sulfasalazine 0.56%. In biological agents, Rituximab (50.4) cost was 
high when compared with other biological agents. The cost of NSAIDs 
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comes around 2.36% of the total drug cost of month. In steroids, the 
cost comes around 0.59 % of the total drug cost. In Group 2 among 
DMARDs, the total cost of Sulfasalazine (25%) was high when 
compared with other DMARDs. Hydroxychloroquine consumes about 
15.5% and Methotrexate (7.05%). In Group 2 there is no biological 
agent taken, the cost of NSAIDs comes around 32% of the total drug 
cost of month. Steroids come around 21.3% of the total drug cost.  
The direct medical cost was higher when compared with group2. 
Direct cost includes the cost of medicines, consultation costs, 
laboratory costs, radiological cost, surgical and hospital costs. Among 
them, drug cost is higher. Vidhya Alex et al. [2], Nagappan et al., [7], 
shows similar reports. Among the direct non-medical costs, 
transportation and food cost is higher than group 2. The indirect cost 
are higher when compared with group 2. Indirect cost components 
include productivity loss of patience and productivity loss of family. 
The average cost is higher in group 1 due to direct and indirect costs. 
There are less pharmacoeconomic studies conducted in India in the 
area of RA. In a study conducted by Vidhya Alex et al., [2], the average 
cost of illness of patients with RA was estimated to be 2229.99/month. 
In detail direct cost accounted for 86.545 of the total cost, slightly 
higher than indirect cost. Out of which 38.21% was consumed by the 
cost of medicine, Laboratory tests were covered by about 15.31 %, 
consultation cost 6.34%, transportation and food cost 23.75%, the 
same result observed. In societal cost analysis of RA in China 
conducted by Chuanhui et al., [8], shows indirect cost covers 10% of 
the total cost of illness. In a study conducted in India by Sukhpreet et 
al.,[9], estimated the average total cost was 999±76 per/month, the 
average monthly direct cost of RA was estimated to be 623±31, the 
average indirect cost was found to be 368±62 per month.  
The treatment cost differs in different countries. In the UK, the 
average annual medical cost was reported to range from £ 3575 to £ 
3638 in a study by N J Cooper et al., [10]. The out of pocket 
expenditure in Germany was found to be £ 417.20 per year which 
accounted for 15.3% of total direct costs. The Gross Domestic 
Product in UK was 41,220 US dollars in 2000. RA patients in UK 
spend only 7.61% of their per capita income for treatment. While in 
Australia only about 1.79% of their per capita income is needed for 
the treatment of RA. Germany per capita GDP income was 42,540 US 
$ and 0.85% of per capita income is spending on the treatment of 
RA. The result of the US-based study showed the mean total annual 
direct medical cost for RA patient was $9,519 in 2001. Medicine cost 
was $6,324(66% of the total), while hospitalization cost was only 
$1,573(17%). Approximately 25% of patients received biological 
therapy. The mean total annual direct cost for the patient who was 
not taking biological was $ 6,164. Per month cost was calculated as 
$513.66. This is higher than our direct cost which is about $35.95 
per month. The discrepancy of annual cost of RA might be due to the 
difference in health care systems, referral practices, financing, GDP, 
and methodologies of studies between India and other countries. 
CONCLUSION 
The study concluded that the burden of RA to the patient is huge. 
Our study helps to improve our knowledge about the burden of RA. 
Prescribing pattern of RA drugs in both hospitals was compared. 
Appropriate standard prescribing guidelines should be developed 
and implementation of the rational drug must be promoted. 
Polypharmacy was reported in group 1 hospital, the progression of 
symptoms was the same in both hospitals, it increases the cost of 
therapy and overall cost of patients. Clinical pharmacists play a 
major role in reducing the irrationality in the prescription by 
assisting the prescriber in selecting the correct drug and dose 
thereby avoiding polypharmacy and improve the patient’s quality of 
life.  
LIMITATION 
Study time period was 6 mo. It requires more time to do it in a large 
population 
The study population involved in the study was less. 
ABBREVIATION 
RA-Rheumatoid Arthritis, DMARD–Disease-Modifying Anti-
Rheumatoid Drugs, RF-Rheumatoid Factor, ESR-Erythrocyte 
Sedimentation Rate, CRP-Couple Reactive Protein. 
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